Previous 10 | Next 10 |
2023-10-26 07:33:19 ET More on Insmed Insmed's Arikayce: A High Flyer With A Heavy Load Insmed Incorporated (INSM) Q2 2023 Earnings Call Transcript Insmed gains as antibacterial agent hits main goal in Phase 3 trial Seeking Alpha’s Quant Rating on Insm...
Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update PR Newswire —ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch an...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Insmed Incorporated (INSM) is expected to report $-1.04 for Q3 2023
2023-10-25 15:10:29 ET More on Insmed Insmed's Arikayce: A High Flyer With A Heavy Load Insmed Incorporated (INSM) Q2 2023 Earnings Call Transcript Insmed gains as antibacterial agent hits main goal in Phase 3 trial Seeking Alpha’s Quant Rating on Insm...
Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI PR Newswire BRIDGEWATER, N.J. , Oct. 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, today announced a colla...
2023-10-15 10:58:47 ET Summary Insmed shows strong Arikayce sales but is financially strained due to surging R&D expenses and increasing operational costs. A diversified but high-risk R&D portfolio raises sustainability concerns, making the company's long-term financial st...
Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023 PR Newswire BRIDGEWATER, N.J. , Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the liv...
Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference PR Newswire BRIDGEWATER, N.J. , Sept. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serio...
2023-09-08 14:09:00 ET Shares of Insmed (NASDAQ: INSM) were up more than 17% for the week as of 10:30 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence . The healthcare company closed last week at $22.64, then rose to a 52-week high of $27.1...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:00:06 ET Vamil Divan from Guggenheim issued a price target of $95.00 for INSM on 2024-07-09 06:44:00. The adjusted price target was set to $95.00. At the time of the announcement, INSM was trading at $70.05. The overall price target consensus is at $72.91 w...
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference PR Newswire —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Bren...